GSK set to achieve 100% renewable electricity at all manufacturing sites in Singapore from 2025

This press release was issued by GlaxoSmithKline (GSK).

• Manufacturing operations in Singapore will move from 3% to 100% renewable electricity, generated directly on-site and procured through renewable energy certificates from solar projects 
• 10-year energy deal with Sembcorp set to increase GSK’s global purchased renewable electricity usage by 9% 
• Important step towards GSK’s global target of 100% purchased renewable electricity across all sites by end 2025

GSK has today announced it has signed a 10-year energy deal with Sembcorp, covering the electricity demand for all three of GSK’s global manufacturing sites in Singapore. This means that from 1 January 2025, all of GSK's manufacturing operations in Singapore will be covered by renewable energy certificates from Sembcorp’s solar projects in Singapore and the 3% already being generated by GSK’s on-site solar panels.

This deal will facilitate the supply of renewable energy certificates for up to 87,600MWh¹ of electricity annually, equivalent to approximately 36,500MT of CO2² , which is set to increase GSK’s global purchased renewable electricity usage by 9%.

GSK’s manufacturing facilities in Singapore are critical for the production of innovative medicines and vaccines for HIV, oncology and infectious diseases. This deal is part of GSK’s ongoing investment and commitment to Singapore, where GSK has had a presence since 1959 and today employs over 1,500 people. It has invested more than S$2.5 billion (£1.5 billion) in Singapore to date.

Healthcare systems globally account for roughly 5% of all emissions, with more than half of these emissions being created in manufacturing supply chains. Renewable electricity deals like this are part of how GSK is working to deliver on its ambitious sustainability targets, and to reduce the environmental impact of developing and manufacturing medicines and vaccines.

Transitioning to renewable energy, which will improve air quality, also has important benefits for respiratory and human health.

At a global level, GSK is committed to an 80% reduction in greenhouse gas emissions across all scopes by 2030 and a 90% reduction by 2045, from a 2020 baseline. This includes a commitment as part of the RE100 initiative to 100% purchased renewable electricity by 2025 and 100% renewable electricity (purchased and generated on-site) by 2030. At the end of 2023 (using the last published data), GSK had reached 83% purchased renewable electricity across its operations.

1 Equivalent to 10MW

2 Calculated using the latest Grid Emission Factor of 0.417kgCO2/KWh for calendar year 2022 published by the Energy Market Authority of Singapore